

<b>Primary System Organ Class Reported Term for the Adverse Event</b>	<b>Placebo N = 86<sup>1</sup></b>	<b>Xanomeline High Dose N = 72<sup>1</sup></b>	<b>Xanomeline Low Dose N = 96<sup>1</sup></b>	<b>Overall N = 254<sup>1</sup></b>
Treatment Emergent AEs	65 (76%)	68 (94%)	84 (88%)	217 (85%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	21 (24%)	36 (50%)	51 (53%)	108 (43%)
APPLICATION SITE PRURITUS	6 (7.0%)	21 (29%)	23 (24%)	50 (20%)
APPLICATION SITE ERYTHEMA	3 (3.5%)	14 (19%)	13 (14%)	30 (12%)
APPLICATION SITE DERMATITIS	5 (5.8%)	7 (9.7%)	9 (9.4%)	21 (8.3%)
APPLICATION SITE IRRITATION	3 (3.5%)	9 (13%)	9 (9.4%)	21 (8.3%)
APPLICATION SITE VESICLES	1 (1.2%)	5 (6.9%)	5 (5.2%)	11 (4.3%)
FATIGUE	1 (1.2%)	5 (6.9%)	5 (5.2%)	11 (4.3%)
OEDEMA PERIPHERAL	2 (2.3%)	2 (2.8%)	1 (1.0%)	5 (2.0%)
APPLICATION SITE SWELLING	0 (0%)	2 (2.8%)	1 (1.0%)	3 (1.2%)
APPLICATION SITE URTICARIA	0 (0%)	1 (1.4%)	2 (2.1%)	3 (1.2%)
CHILLS	1 (1.2%)	1 (1.4%)	1 (1.0%)	3 (1.2%)
MALAISE	0 (0%)	2 (2.8%)	1 (1.0%)	3 (1.2%)
PYREXIA	2 (2.3%)	0 (0%)	1 (1.0%)	3 (1.2%)
APPLICATION SITE PAIN	0 (0%)	2 (2.8%)	0 (0%)	2 (0.8%)
APPLICATION SITE PERSPIRATION	0 (0%)	2 (2.8%)	0 (0%)	2 (0.8%)
APPLICATION SITE REACTION	1 (1.2%)	1 (1.4%)	0 (0%)	2 (0.8%)
<sup>1</sup> n (%)				

<b>Primary System Organ Class Reported Term for the Adverse Event</b>	<b>Placebo N = 86<sup>1</sup></b>	<b>Xanomeline High Dose N = 72<sup>1</sup></b>	<b>Xanomeline Low Dose N = 96<sup>1</sup></b>	<b>Overall N = 254<sup>1</sup></b>
ASTHENIA	1 (1.2%)	0 (0%)	1 (1.0%)	2 (0.8%)
CHEST DISCOMFORT	0 (0%)	1 (1.4%)	1 (1.0%)	2 (0.8%)
CHEST PAIN	0 (0%)	2 (2.8%)	0 (0%)	2 (0.8%)
OEDEMA	0 (0%)	0 (0%)	2 (2.1%)	2 (0.8%)
PAIN	0 (0%)	1 (1.4%)	1 (1.0%)	2 (0.8%)
APPLICATION SITE BLEEDING	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
APPLICATION SITE DESQUAMATION	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
APPLICATION SITE DISCHARGE	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
APPLICATION SITE DISCOLOURATION	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
APPLICATION SITE INDURATION	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
APPLICATION SITE WARMTH	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
FEELING ABNORMAL	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
FEELING COLD	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
INFLAMMATION	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
SECRETION DISCHARGE	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
SUDDEN DEATH	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
SWELLING	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
ULCER	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	20 (23%)	39 (54%)	39 (41%)	98 (39%)
PRURITUS	8 (9.3%)	25 (35%)	21 (22%)	54 (21%)
<sup>1</sup> n (%)				

Primary System Organ Class Reported Term for the Adverse Event	Placebo N = 86 <sup>1</sup>	Xanomeline High Dose N = 72 <sup>1</sup>	Xanomeline Low Dose N = 96 <sup>1</sup>	Overall N = 254 <sup>1</sup>
ERYTHEMA	8 (9.3%)	14 (19%)	14 (15%)	36 (14%)
RASH	5 (5.8%)	8 (11%)	13 (14%)	26 (10%)
HYPERHIDROSIS	2 (2.3%)	8 (11%)	4 (4.2%)	14 (5.5%)
SKIN IRRITATION	3 (3.5%)	5 (6.9%)	6 (6.3%)	14 (5.5%)
BLISTER	0 (0%)	1 (1.4%)	5 (5.2%)	6 (2.4%)
RASH PRURITIC	0 (0%)	2 (2.8%)	1 (1.0%)	3 (1.2%)
PRURITUS GENERALISED	0 (0%)	1 (1.4%)	1 (1.0%)	2 (0.8%)
URTICARIA	0 (0%)	1 (1.4%)	1 (1.0%)	2 (0.8%)
ACTINIC KERATOSIS	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
ALOPECIA	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
COLD SWEAT	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
DERMATITIS CONTACT	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
DRUG ERUPTION	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
RASH ERYTHEMATOUS	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
RASH MACULO-PAPULAR	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
SKIN EXFOLIATION	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
SKIN ODOUR ABNORMAL	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
SKIN ULCER	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
NERVOUS SYSTEM DISORDERS	8 (9.3%)	23 (32%)	22 (23%)	53 (21%)
<sup>1</sup> n (%)				

<b>Primary System Organ Class Reported Term for the Adverse Event</b>	<b>Placebo N = 86<sup>1</sup></b>	<b>Xanomeline High Dose N = 72<sup>1</sup></b>	<b>Xanomeline Low Dose N = 96<sup>1</sup></b>	<b>Overall N = 254<sup>1</sup></b>
DIZZINESS	2 (2.3%)	10 (14%)	9 (9.4%)	21 (8.3%)
HEADACHE	3 (3.5%)	5 (6.9%)	3 (3.1%)	11 (4.3%)
SYNCOPE	0 (0%)	2 (2.8%)	5 (5.2%)	7 (2.8%)
SOMNOLENCE	2 (2.3%)	1 (1.4%)	3 (3.1%)	6 (2.4%)
TRANSIENT ISCHAEMIC ATTACK	0 (0%)	1 (1.4%)	2 (2.1%)	3 (1.2%)
BURNING SENSATION	0 (0%)	2 (2.8%)	0 (0%)	2 (0.8%)
LETHARGY	0 (0%)	1 (1.4%)	1 (1.0%)	2 (0.8%)
AMNESIA	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
BALANCE DISORDER	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
COGNITIVE DISORDER	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
COMPLEX PARTIAL SEIZURES	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
COORDINATION ABNORMAL	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
HEMIANOPIA HOMONYMOUS	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
HYPERMOMNIA	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
PARAESTHESIA	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
PARAESTHESIA ORAL	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
PARKINSON'S DISEASE	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
PAROSMIA	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
PARTIAL SEIZURES WITH SECONDARY GENERALISATION	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
PSYCHOMOTOR HYPERACTIVITY	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)

<sup>1</sup> n (%)

<b>Primary System Organ Class Reported Term for the Adverse Event</b>	<b>Placebo N = 86<sup>1</sup></b>	<b>Xanomeline High Dose N = 72<sup>1</sup></b>	<b>Xanomeline Low Dose N = 96<sup>1</sup></b>	<b>Overall N = 254<sup>1</sup></b>
STUPOR	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
SYNCOPE VASOVAGAL	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
GASTROINTESTINAL DISORDERS	17 (20%)	19 (26%)	15 (16%)	51 (20%)
DIARRHOEA	9 (10%)	3 (4.2%)	5 (5.2%)	17 (6.7%)
VOMITING	3 (3.5%)	6 (8.3%)	4 (4.2%)	13 (5.1%)
NAUSEA	3 (3.5%)	6 (8.3%)	3 (3.1%)	12 (4.7%)
ABDOMINAL PAIN	1 (1.2%)	1 (1.4%)	3 (3.1%)	5 (2.0%)
SALIVARY HYPERSECRETION	0 (0%)	4 (5.6%)	0 (0%)	4 (1.6%)
DYSPEPSIA	1 (1.2%)	0 (0%)	1 (1.0%)	2 (0.8%)
ABDOMINAL DISCOMFORT	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
CONSTIPATION	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
DYSPHAGIA	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
FLATULENCE	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
GASTROINTESTINAL HAEMORRHAGE	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
GASTROOESOPHAGEAL REFLUX DISEASE	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
GLOSSITIS	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
HIATUS HERNIA	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
RECTAL HAEMORRHAGE	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
STOMACH DISCOMFORT	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)

<sup>1</sup> n (%)

<b>Primary System Organ Class Reported Term for the Adverse Event</b>	<b>Placebo N = 86<sup>1</sup></b>	<b>Xanomeline High Dose N = 72<sup>1</sup></b>	<b>Xanomeline Low Dose N = 96<sup>1</sup></b>	<b>Overall N = 254<sup>1</sup></b>
CARDIAC DISORDERS	12 (14%)	14 (19%)	14 (15%)	40 (16%)
SINUS BRADYCARDIA	2 (2.3%)	8 (11%)	7 (7.3%)	17 (6.7%)
MYOCARDIAL INFARCTION	4 (4.7%)	4 (5.6%)	2 (2.1%)	10 (3.9%)
ATRIAL FIBRILLATION	1 (1.2%)	2 (2.8%)	2 (2.1%)	5 (2.0%)
SUPRAVENTRICULAR EXTRASYSTOLES	1 (1.2%)	1 (1.4%)	1 (1.0%)	3 (1.2%)
VENTRICULAR EXTRASYSTOLES	0 (0%)	1 (1.4%)	2 (2.1%)	3 (1.2%)
ATRIAL FLUTTER	0 (0%)	1 (1.4%)	1 (1.0%)	2 (0.8%)
ATRIOVENTRICULAR BLOCK FIRST DEGREE	1 (1.2%)	0 (0%)	1 (1.0%)	2 (0.8%)
BUNDLE BRANCH BLOCK RIGHT	1 (1.2%)	0 (0%)	1 (1.0%)	2 (0.8%)
PALPITATIONS	0 (0%)	0 (0%)	2 (2.1%)	2 (0.8%)
ATRIAL HYPERTROPHY	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
ATRIOVENTRICULAR BLOCK SECOND DEGREE	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
BRADYCARDIA	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
BUNDLE BRANCH BLOCK LEFT	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
CARDIAC DISORDER	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
CARDIAC FAILURE CONGESTIVE	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
SINUS ARRHYTHMIA	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
SUPRAVENTRICULAR TACHYCARDIA	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
TACHYCARDIA	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
<sup>1</sup> n (%)				

<b>Primary System Organ Class Reported Term for the Adverse Event</b>	<b>Placebo N = 86<sup>1</sup></b>	<b>Xanomeline High Dose N = 72<sup>1</sup></b>	<b>Xanomeline Low Dose N = 96<sup>1</sup></b>	<b>Overall N = 254<sup>1</sup></b>
VENTRICULAR HYPERTROPHY	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
WOLFF-PARKINSON-WHITE SYNDROME	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
INFECTIONS AND INFESTATIONS	16 (19%)	13 (18%)	9 (9.4%)	38 (15%)
NASOPHARYNGITIS	2 (2.3%)	6 (8.3%)	4 (4.2%)	12 (4.7%)
UPPER RESPIRATORY TRACT INFECTION	6 (7.0%)	3 (4.2%)	1 (1.0%)	10 (3.9%)
INFLUENZA	1 (1.2%)	1 (1.4%)	1 (1.0%)	3 (1.2%)
URINARY TRACT INFECTION	2 (2.3%)	1 (1.4%)	0 (0%)	3 (1.2%)
CYSTITIS	1 (1.2%)	1 (1.4%)	0 (0%)	2 (0.8%)
EAR INFECTION	2 (2.3%)	0 (0%)	0 (0%)	2 (0.8%)
BRONCHITIS	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
CELLULITIS	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
CERVICITIS	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
GASTROENTERITIS VIRAL	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
HORDEOLUM	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
LOCALISED INFECTION	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
LOWER RESPIRATORY TRACT INFECTION	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
PNEUMONIA	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
RHINITIS	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
VAGINAL MYCOSIS	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
VIRAL INFECTION	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)

<sup>1</sup> n (%)

<b>Primary System Organ Class Reported Term for the Adverse Event</b>	<b>Placebo N = 86<sup>1</sup></b>	<b>Xanomeline High Dose N = 72<sup>1</sup></b>	<b>Xanomeline Low Dose N = 96<sup>1</sup></b>	<b>Overall N = 254<sup>1</sup></b>
PSYCHIATRIC DISORDERS	10 (12%)	7 (9.7%)	11 (11%)	28 (11%)
CONFUSIONAL STATE	2 (2.3%)	1 (1.4%)	3 (3.1%)	6 (2.4%)
AGITATION	2 (2.3%)	0 (0%)	3 (3.1%)	5 (2.0%)
INSOMNIA	2 (2.3%)	2 (2.8%)	0 (0%)	4 (1.6%)
ANXIETY	0 (0%)	0 (0%)	3 (3.1%)	3 (1.2%)
DELUSION	1 (1.2%)	1 (1.4%)	0 (0%)	2 (0.8%)
IRRITABILITY	1 (1.2%)	0 (0%)	1 (1.0%)	2 (0.8%)
COMPLETED SUICIDE	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
DELIRIUM	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
DEPRESSED MOOD	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
DISORIENTATION	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
HALLUCINATION	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
HALLUCINATION, VISUAL	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
LIBIDO DECREASED	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
LISTLESS	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
NIGHTMARE	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
RESTLESSNESS	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	8 (9.3%)	10 (14%)	9 (9.4%)	27 (11%)
COUGH	1 (1.2%)	5 (6.9%)	5 (5.2%)	11 (4.3%)
NASAL CONGESTION	3 (3.5%)	3 (4.2%)	1 (1.0%)	7 (2.8%)

<sup>1</sup> n (%)



<b>Primary System Organ Class Reported Term for the Adverse Event</b>	<b>Placebo N = 86<sup>1</sup></b>	<b>Xanomeline High Dose N = 72<sup>1</sup></b>	<b>Xanomeline Low Dose N = 96<sup>1</sup></b>	<b>Overall N = 254<sup>1</sup></b>
DYSпноEA	1 (1.2%)	1 (1.4%)	1 (1.0%)	3 (1.2%)
EPISTAXIS	0 (0%)	2 (2.8%)	1 (1.0%)	3 (1.2%)
PHARYNGOLARYNGEAL PAIN	0 (0%)	1 (1.4%)	1 (1.0%)	2 (0.8%)
RHINORRHOEA	0 (0%)	1 (1.4%)	1 (1.0%)	2 (0.8%)
ALLERGIC GRANULOMATOUS ANGIITIS	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
DYSPHONIA	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
EMPHYSEMA	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
HAEMOPTYSIS	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
PHARYNGEAL ERYTHEMA	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
POSTNASAL DRIP	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
PRODUCTIVE COUGH	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
RALES	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
RESPIRATORY TRACT CONGESTION	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
INVESTIGATIONS	10 (12%)	5 (6.9%)	7 (7.3%)	22 (8.7%)
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION	4 (4.7%)	0 (0%)	1 (1.0%)	5 (2.0%)
ELECTROCARDIOGRAM T WAVE INVERSION	2 (2.3%)	1 (1.4%)	1 (1.0%)	4 (1.6%)
BLOOD GLUCOSE INCREASED	0 (0%)	1 (1.4%)	1 (1.0%)	2 (0.8%)
ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED	1 (1.2%)	0 (0%)	1 (1.0%)	2 (0.8%)
BIOPSY	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
BIOPSY PROSTATE	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)

<sup>1</sup> n (%)

<b>Primary System Organ Class Reported Term for the Adverse Event</b>	<b>Placebo N = 86<sup>1</sup></b>	<b>Xanomeline High Dose N = 72<sup>1</sup></b>	<b>Xanomeline Low Dose N = 96<sup>1</sup></b>	<b>Overall N = 254<sup>1</sup></b>
BLOOD ALKALINE PHOSPHATASE INCREASED	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
BLOOD CHOLESTEROL INCREASED	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
BLOOD CREATINE PHOSPHOKINASE INCREASED	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
BLOOD URINE PRESENT	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
BODY TEMPERATURE INCREASED	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
CYSTOSCOPY	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
HEART RATE INCREASED	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
HEART RATE IRREGULAR	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
NASAL MUCOSA BIOPSY	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
WEIGHT DECREASED	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	4 (4.7%)	7 (9.7%)	7 (7.3%)	18 (7.1%)
BACK PAIN	1 (1.2%)	3 (4.2%)	1 (1.0%)	5 (2.0%)
ARTHRALGIA	1 (1.2%)	1 (1.4%)	2 (2.1%)	4 (1.6%)
SHOULDER PAIN	1 (1.2%)	0 (0%)	2 (2.1%)	3 (1.2%)
MUSCLE SPASMS	0 (0%)	1 (1.4%)	1 (1.0%)	2 (0.8%)
ARTHRITIS	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
FLANK PAIN	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
MUSCULAR WEAKNESS	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
MYALGIA	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
PAIN IN EXTREMITY	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)

<sup>1</sup> n (%)

<b>Primary System Organ Class Reported Term for the Adverse Event</b>	<b>Placebo N = 86<sup>1</sup></b>	<b>Xanomeline High Dose N = 72<sup>1</sup></b>	<b>Xanomeline Low Dose N = 96<sup>1</sup></b>	<b>Overall N = 254<sup>1</sup></b>
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	4 (4.7%)	5 (6.9%)	5 (5.2%)	14 (5.5%)
CONTUSION	1 (1.2%)	2 (2.8%)	1 (1.0%)	4 (1.6%)
EXCORIATION	2 (2.3%)	1 (1.4%)	1 (1.0%)	4 (1.6%)
FALL	1 (1.2%)	1 (1.4%)	2 (2.1%)	4 (1.6%)
HIP FRACTURE	1 (1.2%)	2 (2.8%)	0 (0%)	3 (1.2%)
SKIN LACERATION	1 (1.2%)	0 (0%)	2 (2.1%)	3 (1.2%)
FACIAL BONES FRACTURE	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
JOINT DISLOCATION	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
WOUND	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
RENAL AND URINARY DISORDERS	4 (4.7%)	3 (4.2%)	3 (3.1%)	10 (3.9%)
MICTURITION URGENCY	1 (1.2%)	1 (1.4%)	1 (1.0%)	3 (1.2%)
DYSURIA	1 (1.2%)	0 (0%)	1 (1.0%)	2 (0.8%)
NEPHROLITHIASIS	1 (1.2%)	1 (1.4%)	0 (0%)	2 (0.8%)
CALCULUS URETHRAL	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
INCONTINENCE	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
POLLAKIURIA	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
METABOLISM AND NUTRITION DISORDERS	6 (7.0%)	2 (2.8%)	1 (1.0%)	9 (3.5%)
DECREASED APPETITE	1 (1.2%)	1 (1.4%)	0 (0%)	2 (0.8%)
FOOD CRAVING	1 (1.2%)	0 (0%)	1 (1.0%)	2 (0.8%)
INCREASED APPETITE	1 (1.2%)	1 (1.4%)	0 (0%)	2 (0.8%)
DEHYDRATION	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)

<sup>1</sup> n (%)

<b>Primary System Organ Class Reported Term for the Adverse Event</b>	<b>Placebo N = 86<sup>1</sup></b>	<b>Xanomeline High Dose N = 72<sup>1</sup></b>	<b>Xanomeline Low Dose N = 96<sup>1</sup></b>	<b>Overall N = 254<sup>1</sup></b>
DIABETES MELLITUS	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
HYPONATRAEMIA	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
VASCULAR DISORDERS	3 (3.5%)	1 (1.4%)	3 (3.1%)	7 (2.8%)
HYPOTENSION	2 (2.3%)	0 (0%)	1 (1.0%)	3 (1.2%)
HYPERTENSION	1 (1.2%)	0 (0%)	1 (1.0%)	2 (0.8%)
HOT FLUSH	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
ORTHOSTATIC HYPOTENSION	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
WOUND HAEMORRHAGE	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
EYE DISORDERS	2 (2.3%)	1 (1.4%)	2 (2.1%)	5 (2.0%)
VISION BLURRED	0 (0%)	1 (1.4%)	1 (1.0%)	2 (0.8%)
CONJUNCTIVAL HAEMORRHAGE	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
CONJUNCTIVITIS	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
EYE ALLERGY	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
EYE PRURITUS	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
EYE SWELLING	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
SURGICAL AND MEDICAL PROCEDURES	2 (2.3%)	2 (2.8%)	1 (1.0%)	5 (2.0%)
CATARACT OPERATION	1 (1.2%)	0 (0%)	1 (1.0%)	2 (0.8%)
ACROCHORDON EXCISION	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
EYE LASER SURGERY	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
SKIN LESION EXCISION	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
EAR AND LABYRINTH DISORDERS	1 (1.2%)	1 (1.4%)	2 (2.1%)	4 (1.6%)
VERTIGO	0 (0%)	1 (1.4%)	1 (1.0%)	2 (0.8%)
<sup>1</sup> n (%)				

<b>Primary System Organ Class Reported Term for the Adverse Event</b>	<b>Placebo N = 86<sup>1</sup></b>	<b>Xanomeline High Dose N = 72<sup>1</sup></b>	<b>Xanomeline Low Dose N = 96<sup>1</sup></b>	<b>Overall N = 254<sup>1</sup></b>
CERUMEN IMPACTION	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
EAR PAIN	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
CONGENITAL, FAMILIAL AND GENETIC DISORDERS	0 (0%)	2 (2.8%)	1 (1.0%)	3 (1.2%)
VENTRICULAR SEPTAL DEFECT	0 (0%)	2 (2.8%)	1 (1.0%)	3 (1.2%)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	0 (0%)	1 (1.4%)	2 (2.1%)	3 (1.2%)
COLON CANCER	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
MALIGNANT FIBROUS HISTIOCYTOMA	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
PROSTATE CANCER	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	2 (2.3%)	1 (1.4%)	0 (0%)	3 (1.2%)
BENIGN PROSTATIC HYPERPLASIA	1 (1.2%)	1 (1.4%)	0 (0%)	2 (0.8%)
PELVIC PAIN	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
HEPATOBIILIARY DISORDERS	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
HYPERBILIRUBINAEMIA	1 (1.2%)	0 (0%)	0 (0%)	1 (0.4%)
IMMUNE SYSTEM DISORDERS	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
HYPERSENSITIVITY	0 (0%)	0 (0%)	1 (1.0%)	1 (0.4%)
SOCIAL CIRCUMSTANCES	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
ALCOHOL USE	0 (0%)	1 (1.4%)	0 (0%)	1 (0.4%)
<sup>1</sup> n (%)				